Semaglutide Clinical Reference

Semaglutide is the most studied GLP-1 incretin receptor agonist in clinical medicine. Across the SUSTAIN program for type 2 diabetes and the STEP program for chronic weight management and obstructive sleep apnea, more than 10,000 adults have been studied in pivotal phase 3 trials. The clinical reference pages below summarize the mechanism, trial outcomes, safety profile, drug interactions, dosing recommendations, and cardiovascular evidence as it stands in 2026. All content is built from FDA prescribing information, published trial reports, and established pharmacology literature — with the understanding that clinical decisions belong to a licensed clinician familiar with the patient's full medical history.

All pages in this section

Mechanism of action — Semaglutide is a long-acting GLP-1 receptor agonist (selective single-agonist of the GLP-1 receptor — not a dual or triple agonist). The albumin-binding side chain extends half-life to ~7 days for once-weekly dosing. Activation produces enhanced glucose-dependent insulin secretion, glucagon suppression, delayed gastric emptying, and central appetite suppression.
STEP trial program — Pivotal phase 3 trials for chronic weight management and obstructive sleep apnea. STEP-1, STEP-2, STEP-3, STEP-4 (withdrawal), STEP-HFpEF (heart failure with preserved ejection fraction), and STEP-5 (head-to-head vs semaglutide 2.4 mg).
SUSTAIN trial program — Pivotal phase 3 trials for type 2 diabetes. SUSTAIN-1 through SUSTAIN-5, including SUSTAIN-2 head-to-head vs semaglutide 1 mg and SUSTAIN-4 cardiovascular safety analysis.
Cardiovascular outcomes — Semaglutide's cardiovascular effects, the ongoing SOUL trial, the SUMMIT trial in HFpEF with obesity, and how semaglutide compares to semaglutide for established cardiovascular benefit.
Contraindications & boxed warnings — Absolute contraindications (MTC, MEN 2, pregnancy, hypersensitivity) and relative contraindications (gastroparesis, prior pancreatitis, severe renal impairment, active diabetic retinopathy).
Drug interactions — Oral contraceptive interaction (clinically important during titration), insulin/sulfonylurea combinations, narrow-therapeutic-index oral medications, and the absence of CYP-mediated interactions due to semaglutide's peptide structure.
Side effects in detail — Gastrointestinal adverse events, pancreatitis, gallbladder events, kidney injury, hypersensitivity, retinopathy, suicidal ideation monitoring, and the boxed thyroid C-cell tumor warning — with mitigation strategies.
Dosing & pharmacology — Standard titration schedule (0.25 mg → 2.4 mg), pharmacokinetic profile (terminal half-life ~5 days), dose selection guidance, missed-dose handling, and storage requirements.

Frequently asked questions

How effective is semaglutide compared to other GLP-1 medications?

Semaglutide consistently produces greater A1C and weight reductions than GLP-1 monoagonists in head-to-head and indirect comparisons. SUSTAIN-2 directly compared semaglutide to semaglutide 1 mg in type 2 diabetes, showing superiority for all three semaglutide doses on A1C and weight endpoints. STEP-5 demonstrated superior weight loss versus semaglutide 2.4 mg in obesity.

Is semaglutide approved for both diabetes and weight loss?

Yes, under two brand names. Ozempic (Novo Nordisk) is FDA-approved for type 2 diabetes (December 5, 2017), with a 2020 label expansion adding cardiovascular risk reduction in T2D adults with established CVD (based on SUSTAIN-6). Wegovy (Novo Nordisk) is FDA-approved for chronic weight management (June 4, 2021) with a label expansion in March 2024 adding cardiovascular risk reduction in adults with obesity and established cardiovascular disease (based on the SELECT trial). Note: the obstructive sleep apnea indication belongs to Zepbound (tirzepatide), not Wegovy. Both contain the same active ingredient, semaglutide.

What clinical monitoring is recommended on semaglutide?

Baseline and periodic assessment of: renal function (eGFR), liver enzymes, glycemic markers in diabetic or prediabetic patients, gallbladder symptoms, signs of pancreatitis, mood and suicidal ideation, and pregnancy status in patients of reproductive potential. Thyroid examination if clinically indicated by symptoms or risk factors.

Are compounded forms of semaglutide clinically equivalent to brand-name?

No head-to-head trials have established clinical equivalence between compounded semaglutide and brand-name Ozempic or Wegovy. Some patients report comparable outcomes; others have reported issues with potency variability or injection-site reactions. Brand-name products carry FDA pre-market review, standardized formulation, and consistent quality controls that compounded products do not.